Red Light Holland Psilocybin Microdosing Capsules Pass 8 Weeks Of Stability Testing

Red Light Holland Corp.

Red Light Holland Corp. (OTCQB:TRUFF) (CSE:TRIP) (FSE:4YX) , a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, announced updates regarding its manufacturing plans to create homogenized natural psilocybin microdosing capsules.

CCrest Laboratories Inc., a Montreal-based cGMP pharmaceutical laboratory that holds a controlled drugs and substances dealer’s license, have finished the first stages of stability testing of Red Light Holland’s Natural psilocybin microdosing capsules which received a Health Canada approved psilocybin import permit. The stability tests were completed after 6 and 8 weeks of storage and are aimed at determining the microdosing capsule’s shelf life. The tests confirmed the capsules maintain the required amount of psychoactive compounds (psilocybin and psilocin) at these respective time points.

The natural psilocybin microdosing capsules are intended to be distributed in Australasia by NUBU Pharmaceuticals, a medical cannabis company based in New Zealand with distribution ties to Australia. The capsules have recently received a complete certificate of analysis confirming they are free of any pesticides, bio contaminants or heavy metals.

“We are extremely pleased these first stability tests were successful, this is an important stage in developing high quality natural psilocybin microdosing capsules. Red Light Holland continues to make great strides with their home grown products and we are enjoying our continued synergies with the goal of helping those in need,” stated Alex Grenier, CEO of Shaman Pharma and president of CCrest Laboratories.

A full stability report is expected after 3 months of testing.

Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Benzinga edit with photos by 4339272 on pixabay and Nathalie De Boever on pexels

Total
0
Shares
Related Posts
Read More

Warner Bros. Discovery Eyes Turnaround with Upcoming Disney+ Bundle and NBA Deal, Analysts Say

Nispel upgraded Warner Bros. Discovery (WBD) from Sector Weight to Overweight with a $11 price target. WBD reported Q1 revenue below consensus, impacted by content impairment. Nispel expects a short-term rally as numbers stabilize and DTC improves. Martin reiterated Hold rating, noting WBD's Max bundle with Disney+ and Hulu launching this summer and potential for larger bundles in the future. Reif Ehrlich maintained Buy rating with $14 price target, citing upcoming catalysts and undemanding valuation. NBA media rights renewal is a key near-term event. WBD's Q1 performance reflects macro and linear ecosystem challenges. Network advertising was -11%.

DIS